Literature DB >> 7584475

Directed cytokine expression in tumour cells in vivo using recombinant vaccinia virus.

B Acres1, K Dott, L Stefani, M P Kieny.   

Abstract

Athymic (Swiss nude) and euthymic (DBA) tumour-bearing mice were injected intravenously with various vaccinia virus (Copenhagen strain) recombinants. Several days after inoculation, tumour cells were found to be well infected with infective vaccinia particles, while organs such as liver, spleen, brain and bone marrow showed barely detectable levels or no signs at all of virus infection. Injection of tumour bearing mice with recombinant VV harbouring the cDNA for either huIL-2 or muIL-6 resulted in detectable lymphokine in the sera of injected animals. Injection of tumour-bearing nude mice with VV-IL-6, but not with VV-IL-2, resulted in significant reduction in growth rate of the tumour, and in some cases, complete rejection of the tumour. Tumour-bearing euthymic mice responded differently. Intravenous injection of VV-IL-2, but not VV-IL-6 resulted in reduced growth rate of 50% of tumours and complete rejection of 17% of tumours.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7584475

Source DB:  PubMed          Journal:  Ther Immunol        ISSN: 0967-0149


  4 in total

1.  Active specific immunotherapy of pulmonary metastasis with vaccinia melanoma oncolysate prepared from granulocyte/macrophage-colony-stimulating-factor-gene-encoded vaccinia virus.

Authors:  D W Ju; X Cao; B Acres
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

Review 2.  Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses.

Authors:  Z Sheng Guo; Stephen H Thorne; David L Bartlett
Journal:  Biochim Biophys Acta       Date:  2008-02-15

3.  Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment.

Authors:  Laetitia Fend; Christelle Remy-Ziller; Johann Foloppe; Juliette Kempf; Sandrine Cochin; Luc Barraud; Nathalie Accart; Philippe Erbs; Sylvie Fournel; Xavier Préville
Journal:  Oncoimmunology       Date:  2015-10-06       Impact factor: 8.110

4.  Oncolytic vaccinia virus: a silver bullet?

Authors:  Monika Lusky; Philippe Erbs; Johann Foloppe; R Bruce Acres
Journal:  Expert Rev Vaccines       Date:  2010-12       Impact factor: 5.683

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.